Browse Products By Molecule:

This web search service is supported by Google Inc.

Products --> Recombinant Proteins

Biotinylated Human IL-17 RA / CD217 Protein, His Tag & Avi Tag (Avitag™)  pdf  pdf  pdf


Cat-Pack Size Price(USD) Qty Inventory Order
Quote for bulk   Worldwide Shipping & Payment
ILR-H82E5-25ug
    $350.00
ILR-H82E5-200ug
    $1380.00
In-stock
Place Purchase Orders


Synonym

CD217,CDw217,IL-17RA,IL17R,CANDF5,hIL-17R

Source

Biotinylated Human IL-17 RA, His Tag (ILR-H82E5) is expressed from human 293 cells (HEK293). It contains AA Leu 33 - Trp 320 (Accession # Q96F46-1).

Predicted N-terminus: Leu 33

Molecular Characterization

IL-17 RA(Leu 33 - Trp 320)Q96F46-1
Poly-his
Avi

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag.

The protein has a calculated MW of 37.2 kDa. The protein migrates as 55-68 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio

The biotin to protein ratio is 0.5-1 as determined by the HABA assay.

Endotoxin

Less than 1.0 EU per μg by the LAL method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

No activity loss is observed after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

SDS-PAGE

Biotinylated Human IL-17 RA, His Tag (Cat. No. ILR-H82E5) SDS-PAGE gel

Biotinylated Human IL-17 RA, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity

Biotinylated Human IL-17 RA, His Tag (Cat. No. ILR-H82E5) ELISA bioactivity

Immobilized Human IL-17A, Tag Free (Cat. No. ILA-H5118) at 2 μg/mL (100 μL/well) can bind Biotinylated Human IL-17 RA, His Tag, Avi Tag (Cat. No. ILR-H82E5) with a linear range of 0.2-8 ng/mL (QC tested).

Request for protocol

 

Background

Interleukin-7 receptor subunit alpha (IL-7 RA or IL7Ra) is also known as cluster of differentiation 127 (CD127). IL-7 RA is a type I cytokine receptor and is a subunit of the functional Interleukin-7 receptor and thymic stromal lymphopoietin (TSLP) receptors. IL-7 RA has been shown to play a critical role in the development of immune cells called lymphocytes - specifically in a process known as V(D)J recombination[citation needed]. This protein is also found to control the accessibility of a region of the genome that contains the T-cell receptor gamma gene, by STAT5 and histone acetylation.

References

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.


Limited Use License

The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrobiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.

Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.

Questions & Comments